Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
4.920
-0.030 (-0.61%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Avalo Therapeutics Stock Forecast
AVTX's stock price has decreased by -62.15% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Avalo Therapeutics stock have an average target of 34.2, with a low estimate of 23 and a high estimate of 48. The average target predicts an increase of 595.12% from the current stock price of 4.92.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 25, 2025.
Analyst Ratings
The average analyst rating for Avalo Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 2 | 2 | 2 | 4 | 4 |
Buy | 1 | 1 | 1 | 2 | 2 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 4 | 4 | 5 | 7 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Jefferies | Jefferies | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +367.48% | Mar 25, 2025 |
Stifel | Stifel | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +631.71% | Mar 25, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 20, 2025 |
Piper Sandler | Piper Sandler | Buy Initiates $48 | Buy | Initiates | $48 | +875.61% | Feb 28, 2025 |
BTIG | BTIG | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +713.01% | Dec 19, 2024 |
Financial Forecast
Revenue This Year
n/a
from 441.00K
Revenue Next Year
n/a
EPS This Year
-5.77
from -20.91
EPS Next Year
-4.62
from -5.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -4.70 | -1.65 | -1.70 | ||
Avg | -5.77 | -4.62 | -4.11 | ||
Low | -8.21 | -7.95 | -5.30 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.